These activities are supported by educational grants from Geron Corporation; Rigel Pharmaceuticals, Inc; and Taiho Oncology.

Advancements in the treatment landscape for myelodysplastic syndromes and leukemias are swiftly reshaping the paradigms of care. The integration of groundbreaking targeted therapies and the nuanced utilization of established treatments are revolutionizing the continuum of patient care. This series of activities is designed to provide participants with recent key updates in these diseases, with commentary from expert faculty on how these data are likely to impact treatment in the future.